Poor prognostic factors in patients hospitalized for COVID-19
DOI:
https://doi.org/10.23938/ASSN.1000Keywords:
COVID-19, Hospitalization, Mortality, Intensive care units, Acute myeloid leukemia. Genetic marker. Mutation. Whole-genome sequencing. Prognosis.Abstract
Background. The clinical spectrum of COVID-19 varies from no or mild symptoms to pneumonia with fatal complications. The aim of the study was to find predictors of mortality and admission in the intensive care unit (ICU) in patients hospitalized for COVID-19.
Methods. Retrospective study of a cohort of patients admitted for COVID-19 between March 2020 and February 2021. Demographic, clinical, radiological and laboratory variables were described at admission. Independent predictors of mortality and ICU admission were identified by means of backward stepwise logistic regression and described in terms of odds ratio (OR) and 95% confidence interval (95%CI).
Results. A total of 883 patients were included, 51.8% men with a mean age of 68; 1.8% readmissions. 17.6% of patients died (n=154). The independent predictors of mortality were age (OR=1.071; 95%CI: 1.046-1.095), percentage of oxygen saturation (SatO2) (OR=0.938; 95%CI: 0.903-0.974), diastolic blood pressure (DBP, OR= 0.972; 95%CI: 0.955-0.989), creatinine (OR=1.516; 95%CI: 1.088-2.113), INR (OR=1.199; 95%CI: 1.012-1.419) and sodium (OR=1.082; 95%CI: 1.037-1.128). Eight percent of patients were admitted to ICU; the independent predictors were: male sex (OR=2.079; 95%CI: 1.099-3.935), age (OR=0.960; 95%CI: 0.942-0.979), SatO2 (OR=0.925; 95%CI: 0.889-0.962), creatinine (OR=1.551; 95%CI: 1.118-2.152) and C-reactive protein (CRP, OR=1.003; 95%CI: 1.000-1.007).
Conclusion. The identification of independent predictors of mortality (age, SatO2, DBP, creatinine, INR, sodium) and ICU admission (sex, age, SatO2, creatinine, and CRP) allowed for the stratification of patients to adapt clinical care protocols to these findings, thereby improving medical decisions.
Downloads
References
SALZBERGER B, BUDER F, LAMPL B, EHRENSTEIN B, HITZENBICHLER F, HANSES F. [Epidemiology of SARS-CoV-2 infection and COVID-19]. Internist 2020; 61: 782-788. https://doi.org/10.1007/s00108-020-00834-9
GUTIÉRREZ-GUTIÉRREZ B, DEL TORO MD, BOROBIA AM, CARCAS A, JARRÍN I, YLLESCAS M et al. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infect Dis 2021; 21: 783-792. https://doi.org/10.1016/S1473-3099(21)00019-0
BERENGUER J, RYAN P, RODRÍGUEZ-BAÑO J, CARCAS A, JARRÍN I, YLLESCAS M et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect 2020; 26: 1525-1536. https://doi.org/10.1016/j.cmi.2020.07.024
WADHERA RK, WADHERA P, GABA P, FIGUEROA JF, JOYNT MADDOX KE, YEH RW et al. Variation in COVID-19 hospitalizations and deaths across New York city boroughs. JAMA 2020; 323: 2192. https://doi.org/10.1001/jama.2020.7197
SALTO-ALEJANDRE S, ROCA-OPORTO C, MARTÍN-GUTIÉRREZ G, AVILÉS MD, GÓMEZ-GONZÁLEZ C, NAVARRO-AMUEDO MD et al. A quick prediction tool for unfavourable outcome in COVID-19 inpatients: Development and internal validation. J Infect 2021; 82: e11-e15. https://doi.org/10.1016/j.jinf.2020.09.023
GALLOWAY JB, NORTON S, BARKER RD, BROOKES A, CAREY I, CLARKE BD et al. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study. J Infect 2020; 81: 282-288. https://doi.org/10.1016/j.jinf.2020.05.064
DU R-H, LIU L-M, YIN W, WANG W, GUAN L-L, YUAN ML et al. Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China. Ann Am Thorac Soc 2020; 17: 839-846. https://doi.org/10.1513/AnnalsATS.202003-225OC
GUAN W, NI Z, HU Y, LIANG W-H, OU C-Q, HE J-X et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720. https://doi.org/10.1056/NEJMoa2002032
WANG D, HU B, HU C, ZHU F, LIU X, ZHANG J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061. https://doi.org/10.1001/jama.2020.1585
RICHARDSON S, HIRSCH JS, NARASIMHAN M, CRAWFORD JM, MCGINN T, DAVIDSON KW et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city Area. JAMA 2020; 323: 2052. https://doi.org/10.1001/jama.2020.6775
PAN F, YANG L, LI Y, LIANG B, LI L, YE T et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci 2020; 17: 1281-1292. https://doi.org/10.7150/ijms.46614
LIANG W, GUAN W, LI C, LI Y, LIANG H, ZHAO Y et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J 2020; 55: 2000562. https://doi.org/10.1183/13993003.00562-2020
ZHOU F, YU T, DU R, FAN G, LIU Y, LIU Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Epidemiology Working Group for NCIP epidemic response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chinese J Epidemiol 2020; 41: 145-151.
YANG X, YU Y, XU J, SHU H, XIA J, LIU H et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475-481. https://doi.org/10.1016/S2213-2600(20)30079-5
WU C, CHEN X, CAI Y, XIA J, ZHOU X, XU S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934. https://doi.org/10.1001/jamainternmed.2020.0994
HUANG Z, FU Z, HUANG W, HUANG K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis. Am J Emerg Med 2020; 38: 641-647. https://doi.org/10.1016/j.ajem.2019.10.023
LAGUNAS‐RANGEL FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis. J Med Virol 2020; 92: 1733-1734. https://doi.org/10.1002/jmv.25819
LIU Y, DU X, CHEN J, JIN Y, PENG L, WANG HHX et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 2020; 81: e6-e12. https://doi.org/10.1016/j.jinf.2020.04.002
GRASSELLI G, GRECO M, ZANELLA A, ALBANO G, ANTONELLI M, BELLANI G et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020; 180: 1345. https://doi.org/10.1001/jamainternmed.2020.3539
PIETROBON AJ, TEIXEIRA FME, SATO MN. I mmunosenescence and Inflammaging: Risk Factors of severe COVID-19 in older people. Front Immunol 2020; 11. https://doi.org/10.3389/fimmu.2020.579220
PARANJPE I, RUSSAK A, DE FREITAS JK, LALA A, MIOTTO R, VAID A et al. Clinical characteristics of hospitalized COVID-19 patients in New York City. [Preprint]. medRxiv 2020: 04.19.20062117. https://doi.org/10.1101/2020.04.19.20062117
GOYAL P, CHOI JJ, PINHEIRO LC, SCHENCK EJ, CHEN R, JABRI A. Características clínicas de COVID-19 en la ciudad de Nueva York. N Engl J Med 2020; 382: 2372–2374. https://doi.org/10.1056/NEJMc2010419
DOCHERTY AB, HARRISON EM, GREEN CA, HARDWICK HE, PIUS R, NORMAN L. Características de 20133 pacientes del Reino Unido hospitalizados con COVID-19 utilizando el Protocolo de caracterización clínica de la OMS ISARIC: estudio de cohorte observacional prospectivo. BMJ 2020; 369: m1985. https://doi.org/10.1136/bmj.m1985
KLEIN SL, FLANAGAN KL. Diferencias de sexo en las respuestas inmunes. Nat Rev Immunol 2016; 16: 626–638. https://doi.org/10.1038/nri.2016.90
BOROBIA AM, CARCAS AJ, ARNALICH F. Una cohorte de pacientes con COVID-19 en un importante hospital universitario de Europa. J Clin Med 2020; 9. https://doi.org/10.3390/jcm9061733
ZHAO Z, CHEN A, HOU W, GRAHAM JM, LI H, RICHMAN PS et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PLoS One 2020; 15: e0236618. https://doi.org/10.1371/journal.pone.0236618
LI X, GE P, ZHU J, LI H, GRAHAM J, SINGER A et al. Deep learning prediction of likelihood of ICU admission and mortality in COVID-19 patients using clinical variables. Peer J 2020; 8: e10337. https://doi.org/10.7717/peerj.10337
FERRANDO C, MELLADO-ARTIGAS R, GEA A, ARRUTI E, ALDECOA C, BORDELL A et al. Características, evolución clínica y factores asociados a la mortalidad en UCI de los pacientes críticos infectados por SARS-CoV-2 en España: estudio prospectivo, de cohorte y multicéntrico. Rev Esp Anestesiol Reanim 2020; 67: 425-437. https://doi.org/10.1016/j.redar.2020.07.00
ANDO M, SHIBUYA A, TSUCHIYA K, AKIBA T, NITTA K. Reduced expression of Toll-like receptor 4 contributes to impaired cytokine response of monocytes in uremic patients. Kidney Int 2006; 70: 358-362. https://doi.org/10.1038/sj.ki.5001548
GIRNDT M, SESTER M, SESTER U, KAUL H, KÖHLER H. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001; 59: 1382-1389. https://doi.org/10.1046/j.1523-1755.2001.0590041382.x
SYED-AHMED M, NARAYANAN M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis 2019; 26: 8-15. https://doi.org/10.1053/j.ackd.2019.01.004
FLYTHE JE, ASSIMON MM, TUGMAN MJ, CHANG EH, GUPTA S, SHAH J et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis 2021; 77: 190-203.e1. https://doi.org/10.1053/j.ajkd.2020.09.003
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
